Hospital
Hti Memorial Hospital Corporation
Hti Memorial Hospital Corporation was paid $23.63M by Medicaid between Jan 2018 and Dec 2024, across 61 billing codes. Its largest line is 99283, emergency room visit (moderate) — 47% of everything it billed.
33Billing provider infoHTI MEMORIAL HOSPITAL CORPORATION
NASHVILLE, TN 37207
NASHVILLE, TN 37207
33aNPI1295780476assigned 05/24/2006
33bProvider typePsychiatric Hospital
28Total paid$23.63M
24GClaims434,176
24DCodes billed61
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital providers in Tennessee
Rank by total paid#2 of 15
Median peer was paid$356K
This provider vs. median66×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 74,032 | $4.36M | |
| 2019 | 70,569 | $3.96M | |
| 2020 | 49,655 | $2.84M | |
| 2021 | 56,440 | $3.19M | |
| 2022 | 67,299 | $3.53M | |
| 2023 | 79,032 | $3.58M | |
| 2024incomplete | 37,149 | $2.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 47% | 52,074 | 46,595 | $11.07M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 44% | 49,754 | 41,609 | $10.43M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.8% | 26,442 | 22,118 | $1.13M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 9,322 | 8,234 | $215K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 837 | 658 | $204K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 932 | 883 | $133K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,610 | 5,625 | $116K |
| G0378 | Hospital observation service, per hour | <1% | 214 | 146 | $60K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,416 | 3,550 | $46K |
| 80053 | Comprehensive metabolic panel | <1% | 45,113 | 37,372 | $34K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 24,032 | 19,236 | $28K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,283 | 5,190 | $23K |
49 more codes
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,075 | $22K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 798 | $21K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 141 | $16K |
| 85027 | <1% | 56,744 | $15K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,395 | $12K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 732 | $10K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,022 | $7K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,859 | $6K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,018 | $5K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 10,631 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,959 | $4K |
| 80320 | <1% | 47 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 33 | $3K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 92 | $3K |
| 83690 | <1% | 12,548 | $2K | |
| 81001 | <1% | 19,712 | $2K | |
| 84484 | <1% | 9,108 | $1K | |
| 84703 | <1% | 16,693 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,421 | $666.78 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 36 | $382.80 |
| 87070 | <1% | 908 | $319.02 | |
| 80179 | <1% | 455 | $291.66 | |
| 80143 | <1% | 479 | $291.66 | |
| 72082 | <1% | 16 | $286.24 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,873 | $245.62 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,406 | $207.76 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,074 | $202.44 |
| 82077 | <1% | 850 | $155.07 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,071 | $146.82 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 77 | $139.34 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,228 | $122.85 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 163 | $80.13 |
| 85610 | <1% | 1,652 | $79.97 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 445 | $67.56 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,017 | $35.77 |
| 85730 | <1% | 324 | $23.01 | |
| 81003 | <1% | 2,667 | $15.47 | |
| 83605 | <1% | 74 | $11.21 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 244 | $7.02 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 70 | $4.02 |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 1,225 | $0.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 13 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 1,555 | $0.00 |
| 72125 | Computed tomography, cervical spine; without contrast material | 0% | 570 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 577 | $0.00 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 13 | $0.00 |
| 85380 | 0% | 12 | $0.00 | |
| 84702 | 0% | 13 | $0.00 | |
| 73130 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMSON, SAM (CFO)